AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of $340m.
AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.
STADA Group, a German generic drug manufacturer, has agreed to acquire the prescription and consumer health business of Ukrainian pharmaceutical producer Biopharma for an undisclosed price.
Swiss pharmaceutical company Novartis has opened a new manufacturing facility for cell and gene therapies at Stein in Switzerland.
Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.
Lupin has signed a definitive agreement to sell the entire stake in its Japanese subsidiary Kyowa Pharmaceutical to Unison, a Japanese private equity fund, for JPY57.36bn ($526m).
Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.
Japan-based Takeda Pharmaceutical has opened a new dengue vaccine manufacturing facility in Singen, Germany.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.